In its latest 10-Q filing, MAIA Biotechnology disclosed significant milestones including the activation of its first U.S. clinical site for the Phase 2 expansion trial assessing ateganosine in advanced non-small cell lung cancer (NSCLC). The company secured $33 million in financing to support its ongoing pivotal Phase 3 trial (THIO-104) targeting chemo- and checkpoint inhibitor-resistant NSCLC patients. MAIA’s business model centers on ateganosine — a novel telomere-targeted immunotherapy — augmented by collaborations with Regeneron and BeOne Medicines. While the clinical pipeline shows promise, operational execution, funding sustainability, and competition from established oncology therapies remain critical risk vectors to monitor.